Organogenesis Holdings Inc. (ORGO) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture: strong revenue growth and improved net income are positive, but increased operating expenses and cash position decline are concerning. The Q&A reveals uncertainties in FDA approval timelines and unclear management responses on financial guidance, which may dampen investor confidence. The company's guidance is cautious, with potential for modest revenue growth. Overall, the sentiment is balanced, leading to a neutral prediction for stock movement.
Key Financial Performance
Advanced Wound Care product sales $141.5 million, up 31% year-over-year. The increase was driven by strong commercial team execution and momentum from the end of Q2.
Surgical & Sports Medicine product sales $9 million, up 25% year-over-year. Growth was primarily due to an increase across the PuraPly family of products.
Net product revenue $150.5 million, up 31% year-over-year and up 49% sequentially. This exceeded the high end of expectations due to better-than-expected growth in Advanced Wound Care and Surgical & Sports Medicine products.
Gross profit $114.2 million or 76% of net product revenue, compared to 77% last year. The slight decrease was due to a shift in product mix.
Operating expenses $130.1 million, up 19% year-over-year. Excluding cost of goods sold, non-GAAP operating expenses were $93.9 million, up 14% year-over-year. The increase was driven by a rise in SG&A expenses, R&D expenses, and a write-down of certain nonrecurring expenses.
Operating income $20.7 million, up from $6.2 million last year, an increase of $14.5 million. Non-GAAP operating income was $23 million, up from $7.1 million last year.
GAAP net income $21.6 million, up from $12.3 million last year, an increase of $9.2 million.
Adjusted EBITDA $30.1 million, up from $13.4 million last year.
Cash, cash equivalents, and restricted cash $64.4 million as of September 30, 2025, down from $136.2 million as of December 31, 2024. The decrease reflects changes in working capital and other financial activities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Advanced Wound Care products: Sales increased 31% year-over-year in Q3, driven by strong execution and customer relationships.
Surgical & Sports Medicine products: Sales increased 25% year-over-year in Q3, with growth attributed to the PuraPly family of products.
ReNu program: The second Phase III trial did not achieve statistical significance for its primary endpoint but showed numerical improvement in baseline pain reduction. Combined results from Phase III trials support potential FDA approval for knee osteoarthritis treatment.
CMS Medicare policy changes: CMS finalized skin substitute classifications and payment methodology, recognizing clinical differentiation of PMA products. This reform is expected to expand access and stabilize the market.
Revenue performance: Q3 net product revenue reached $150.5 million, up 31% year-over-year, exceeding guidance.
Profitability: Gross profit for Q3 was $114.2 million (76% of revenue). Operating income increased to $20.7 million from $6.2 million last year.
Financial guidance for 2025: Revenue guidance updated to $500-$525 million, with Advanced Wound Care products expected to contribute $470-$490 million.
Clinical and regulatory advancements: FDA granted RMAT designation to ReNu for knee osteoarthritis. A December 12 meeting with the FDA is scheduled to discuss BLA submission.
Market positioning: Organogenesis is leveraging its diverse portfolio and clinical evidence to maintain leadership in the skin substitute market, with plans to reintroduce Dermagraft and expand product coverage.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Competitor Pricing Strategies: The company faces aggressive pricing strategies from competitors, which could impact its market share and profitability.
Regulatory Challenges: The second Phase III trial of ReNu did not achieve statistical significance for its primary endpoint, which may delay or complicate FDA approval for the product.
Medicare Policy Changes: While the new CMS policy is seen as a positive development, there is uncertainty regarding its implementation and potential impact on the company's products and market dynamics.
Clinical Trial Delays: The company did not meet the November 1 submission deadline for new data for LCD coverage consideration in 2026 for certain products, which could delay market access and revenue generation.
Increased Operating Expenses: Operating expenses increased by 19% year-over-year, driven by higher SG&A and R&D costs, which could pressure profitability.
Cash Position Decline: The company's cash, cash equivalents, and restricted cash decreased significantly from $136.2 million to $64.4 million within nine months, which may limit financial flexibility.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2025 Revenue Guidance: The company expects net revenue of between $500 million and $525 million, representing a year-over-year increase in the range of 4% to 9%. Advanced Wound Care products are projected to generate between $470 million and $490 million, a year-over-year increase of 4% to 8%. Surgical & Sports Medicine products are expected to generate between $30 million and $35 million, a year-over-year increase of 6% to 23%.
Profitability and EBITDA Guidance for 2025: The company expects GAAP net income in the range of $8.6 million to $25.4 million, compared to a previous range of a net loss of $6.4 million to net income of $16.4 million. EBITDA is projected to be between $19.1 million and $41.9 million, compared to $6.2 million to $37 million previously. Adjusted EBITDA is expected to range from $45.5 million to $68.3 million, compared to $31.1 million to $61.9 million previously.
Gross Margins and Operating Expenses for 2025: Gross margins are expected to be in the range of approximately 74% to 76%. GAAP operating expenses, excluding cost of goods sold, are projected to increase by 1% to 2% year-over-year. Non-GAAP operating expenses, excluding specific noncash and nonrecurring costs, are expected to increase by 3% to 5% year-over-year.
CMS Policy Impact and Market Position for 2026: The company anticipates significant opportunities due to CMS's new payment reform policy for skin substitutes, effective January 1, 2026. This policy is expected to expand access to PMA products and ensure consistent payment approaches across care sites. Organogenesis believes it is well-positioned to capitalize on these changes, with a strong portfolio of covered products and plans to leverage its development engine for innovation and market penetration.
ReNu Program and FDA Submission: The company plans to submit a Biologic License Application (BLA) for ReNu, targeting approval for pain symptoms associated with knee osteoarthritis. A meeting with the FDA is scheduled for December 12 to discuss the submission, which will include combined efficacy analysis from two Phase III studies.
Future Strategic Investments and Product Launches: Organogenesis plans to advance its competitive position beyond 2026 by leveraging its development engine for new innovations, reintroducing products like Dermagraft, and expanding clinical evidence to support its technologies.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Net income to common: Net income to common for the third quarter was $14.5 million compared to a net income of $12.3 million last year. As a reminder, net income to common includes the impacts of the cumulative dividend, the noncash accretion to redemption value on our convertible preferred stock and undistributed earnings allocated to participating redeemable convertible preferred stock.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How are conversations with the clinical community progressing regarding changes in physician behavior following the PFS?
A:Management is starting to see some administrative behavior changes, such as clinicians moving to products on the approved LCD list and contracts being processed to include these products. However, no sales behavior changes have been observed yet.
Q:What steps will the company take next year to generate awareness about its products as incremental volume opens up?
A:The company will leverage its strong brand equity and focus on the clinical efficacy of its portfolio. They will continue to emphasize the clinical evidence supporting their products, their likelihood of reimbursement, and their inclusion on the LCD list.
Q:How might the new physician fee schedule rates for 2026 impact margins?
A:Management highlighted several factors, including the removal of over 200 products from coverage under the LCD, the inclusion of their three commercialized products, and the leveling of financial incentives in the market. They expect growth drivers, margin improvements, and cash flow enhancements, despite a decline in ASPs across the market.
Q:Was the company surprised by the final rate of $127 for the physician fee schedule?
A:No, the company expected the final rate to align with the proposed rule. They believe CMS will eventually differentiate PMAs from 510(k)s and 361s, potentially leading to higher reimbursement rates for PMAs over time.
Q:Are the initial approval timelines for ReNu still on track given the recent data readout?
A:The company believes there may be a two-month delay in the approval timeline, but they are still aiming to file in modular form in December, pending a successful meeting with the FDA.
Q:Review of Unclear Management Responses
A:Management avoided providing specific financial guidance for 2026 and used general language when discussing potential changes in reimbursement rates and market dynamics. They also did not provide a clear answer on whether the $127 rate would curtail care or how CMS might adjust rates in the future.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advanced Therapy
Affinity
Americans meeting
Apligraf product
BLA approval
CMS access
CMS skin
CMS step
Chair Holdings
DFU CMS
DFU VLU
FDA ReNu
FDA category
FDA license
III study
III trial
LCDs
Medicine
PMA product
Phase III
analysis
customer relationship
improvement pain
investment
knee osteoarthritis
pain reduction
policy
portfolio
position
product DFU
reduction result
result Phase
space
step payment
substitute market
technology
ORGO Transcript
Organogenesis Holdings Inc. (ORGO) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call indicates strong financial performance with a 10% revenue increase and a 25% rise in net income. Gross margins also improved by 2%, and cash flow from operations increased by 15%. These positive financial metrics, coupled with optimistic guidance for revenue growth and margin improvement, suggest a positive stock price movement. However, the lack of discussion on strategic initiatives and risks tempers the outlook slightly, leading to a 'Positive' sentiment rather than 'Strong positive.'
Organogenesis Holdings Inc. (ORGO) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call summary indicates strong financial performance with a 10% revenue increase, improved gross margins, and a 25% rise in net income. Strategic initiatives focus on product innovation and market expansion, supported by favorable market trends. The positive outlook for revenue and margin improvements in 2026 further boosts sentiment. Despite potential regulatory risks, the overall tone is optimistic, suggesting a positive stock price movement over the next two weeks.
Organogenesis Holdings Inc. (ORGO) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call presents a mixed picture: strong revenue growth and improved net income are positive, but increased operating expenses and cash position decline are concerning. The Q&A reveals uncertainties in FDA approval timelines and unclear management responses on financial guidance, which may dampen investor confidence. The company's guidance is cautious, with potential for modest revenue growth. Overall, the sentiment is balanced, leading to a neutral prediction for stock movement.
Organogenesis Holdings Inc. (ORGO) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call reveals several negative aspects: declining net product revenue, a significant EBITDA loss, and reduced cash reserves. Despite some positive notes in surgical product revenue and potential CMS reimbursement changes, the company's heavy dependence on regulatory approvals and operational risks in new facilities pose significant challenges. The Q&A section revealed reduced guidance and aggressive market behavior, further contributing to a negative sentiment. Overall, these factors suggest a negative stock price movement in the short term.
ORGO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
